Summary
Vertex Pharmaceuticals Incorporated filed an 8-K report on April 26, 2004, to disclose its financial results for the quarter ended March 31, 2004. The primary purpose of this filing is to provide investors with updated financial performance information. While the 8-K itself does not contain the detailed financial figures, it references a press release (Exhibit 99.1) that was issued on the same date, April 26, 2004. Investors and analysts should refer to this attached press release for the specific quarterly earnings, revenue, expenses, and any other significant financial metrics related to the first quarter of 2004. This type of filing is crucial for understanding the company's operational and financial health during the reporting period.
Key Highlights
- 1Vertex Pharmaceuticals (VRTX) filed an 8-K on April 26, 2004.
- 2The filing pertains to the company's financial results for the quarter ended March 31, 2004.
- 3A press release containing the detailed financial results was issued on April 26, 2004.
- 4The press release is attached as Exhibit 99.1 to the Form 8-K.
- 5This report serves to formally announce the company's quarterly financial performance to the public.
- 6Investors should consult the referenced press release for specific financial data and operational updates.